About this trial
Premature ovarian failure (POI) is a loss of normal function before age 40, leading to infertility and hypoestrogenism. About 1% of women younger than 40 years old and 0.1% before 30 are affected. Most patients already had impaired or complete loss of fecundity when diagnosed. Hence, the treatment of POI is particularly tough. Currently, no optimal regimen exists to ameliorate ovarian function.
Eligibility criteria
Qualifiers
Signed and dated informed consent
Women 40 years of age and younger with documented primary ovarian insufficiency (12).
Normal Karyotype
BMI </= 35 kg/m2
Disqualifiers
Premature ovarian failure due to a genetic origin, such as Turner's Syndrome or chromosomal abnormality.
Oncological diseases (specially, skeletal system and blood).
Autoimmune diseases, for example, lupus erythematosus, etc.
Previous treatments including radiotherapy or chemotherapy.
Trial design
Treatments tested in this trial
- Ovarian puncture
- Hormonal blood Test
- Transvaginal ultrasound